Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : Gets Funds From Bill & Melinda Gates Foundation to Treat Cryptosporidiosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2018 | 07:50am CEST
   By Marc Bisbal Arias 
 

Novartis AG (NOVN.EB) said Wednesday that it has signed an alliance with the Bill & Melinda Gates Foundation for further development of a drug that treats the diarrheal disease cryptosporidiosis.

The Swiss company said that the Gates Foundation will provide $6.5 million to support the development of Novartis's drug candidate KDU731.

"Cryptosporidiosis is the second leading cause of infectious diarrhea in children under two years of age," Novartis said. Diarrheal diseases cause around 525,000 deaths a year.

Write to Marc Bisbal Arias at marc.bisbalarias@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
08/17Bach proposes CAR T payment options for CMS
AQ
08/16NOVARTIS : "Ophthalmic Surgical Image Processing" in Patent Application Approval..
AQ
08/16NOVARTIS : Patent Issued for Yeast Display Systems (USPTO 10,041,064)
AQ
08/16NOVARTIS : Patent Application Titled "Frequency-Based Mode Mixing For Surgical L..
AQ
08/16NOVARTIS : Patent Application Titled "Pixelated Array Optics For Mixed Mode Surg..
AQ
08/16NOVARTIS : Researchers Submit Patent Application, "System And Method For Cutting..
AQ
08/16NOVARTIS : "Fiber-Based Mode Mixing Techniques For Surgical Laser Illumination" ..
AQ
08/16NOVARTIS : Patent Issued for Internally Illuminated Surgical Probe (USPTO 10,039..
AQ
08/16NOVARTIS : Patent Application Titled "Mechanical Optics For Mixed Mode Surgical ..
AQ
08/16NOVARTIS : Researchers Submit Patent Application, "Focusing Optics For Mixed Mod..
AQ
More news
News from SeekingAlpha
08/15Express Scripts quietly building dispensing business for pricey meds 
08/14VERASTEM : An Undervalued Rare Oncology Gem With Big Upcoming Catalysts 
08/14ONE YEAR LATER : Lessons Learned In CAR-T 
08/14Eton Pharmaceuticals Files For U.S. IPO 
08/14SPARK THERAPEUTICS : This Appears To Be A Dip Worth Buying 
Financials ($)
Sales 2018 52 365 M
EBIT 2018 13 043 M
Net income 2018 11 118 M
Debt 2018 14 565 M
Yield 2018 3,59%
P/E ratio 2018 14,52
P/E ratio 2019 20,22
EV / Sales 2018 4,24x
EV / Sales 2019 4,09x
Capitalization 208 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 89,6 $
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-0.83%207 488
JOHNSON & JOHNSON-5.18%347 417
PFIZER14.36%238 136
ROCHE HOLDING LTD.-2.96%206 696
MERCK AND COMPANY22.36%176 752
AMGEN12.28%126 710